InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,064.20
(
0.91%
)
US TECH 100
17,174.80
(
1.86%
)
Dow Jones
38,225.66
(
0.85%
)
Brent Oil
83.64
(
0.12%
)
Bitcoin
58,845.58
(
1.04%
)
Post# of 251689
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 827
Posts 119553
Boards Moderated 15
Alias Born 09/05/2002

DewDiligence

Member Level

Re: None

Monday, 11/16/2015 9:56:24 AM

Monday, November 16, 2015 9:56:24 AM

Post# of 251689
ABBA/ENTA—Next-gen ABT-493/ABT-530 regimen at highest doses tested in phase-2b trials (without ribavirin) produced SVR12 rates in GT1 12w, GT1 8w, GT2 12w, and GT3 12w of: 100% (40/40), 97% (33/34), 100% (24/24), and 93% (28/30), respectively:

http://finance.yahoo.com/news/enanta-pharmaceuticals-announces-investigational-regimen-140900626.html

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up